Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical implications of molecular heterogeneity in triple negative breast cancer.

Breast (Edinburgh, Scotland) - 1 Nov 2015

Lehmann Brian D, Pietenpol Jennifer A

Abstract excerpt

Triple negative breast cancer (TNBC) is a molecularly heterogeneous disease lacking recurrent targetable alterations and thus therapeutic advances have been challenging. The absence of ER, PR and HER2 amplifications, leaves combination chemotherapy as the standard of care treatment option in the adjuvant, neoadjuvant and metastatic settings. Recently, multiple studies have shed some light on the heterogeneity of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Genetic Heterogeneity
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Patient Selection

Share to Phenotype

Share to Transcription, Genetic

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 26253813
DOI: 10.1016/j.breast.2015.07.009
PMCID: PMC4641762

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical implications of molecular heterogeneity in triple negative breast cancer.PMID 26253813Read ↗

Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.Semantic proximity Read ↗

Triple-negative breast cancer and the need for new therapeutic targets.Semantic proximity Read ↗

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Semantic proximity Read ↗

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapiesSemantic proximity Read ↗

The Molecular Landscape and Utility of Multiomic Analyses in Triple Negative Breast Cancer: Further Subtyping and Exploring Novel Biomarkers and Therapeutic TargetsSemantic proximity Read ↗

Update on triple‐negative breast cancers – highlighting subtyping update and treatment implicationSemantic proximity Read ↗

New Biomarkers and Treatment Advances in Triple-Negative Breast CancerSemantic proximity Read ↗

Molecular subtypes and precision treatment of triple-negative breast cancerSemantic proximity Read ↗

Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast CancerSemantic proximity Read ↗

Molecular Basis of Triple Negative Breast Cancer and Implications for TherapySemantic proximity Read ↗

Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer.Semantic proximity Read ↗

Therapeutic Advances and New Directions for Triple-Negative Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.